ADMA Biologics Inc. (NASDAQ:ADMA) is down 15% in a month. The company that its CEO and president Adam Grossman will participate in the virtual fireside discussion at the 19th Morgan Stanley Annual Global Healthcare Conference on September 9, 2021.
Recently the company released its fiscal Q2 financial results for the three months endingJune 30, 2021, and provided highlights of recent accomplishments and progress. The company realized total revenue of $17.8 million in Q2 2021, a 129% YoY increased from a year ago. Consolidated net loss during the quarter was $18.9 million or $0.15 per diluted and basic share compared to $20 million or $0.23per share in Q2 2020.
During the quarter, the company completed PAI, paving the way for the 2H 2021 approval of VanRx. Additionally, the considerable operating efficiencies anticipated due to VanRx approval will propel the company into an elite drug manufacturer. The company expanded its IG product offerings suite with the addition of NAB-HB and BIVIGAM vial sizes, enhancing its go-to-market offerings. ADMA is worth watching in the coming months.
On Thursday, ADMA stock gained 1.50% at $1.35 with more than 806K shares, compared to its average volume of 2.41 million shares. The stock has moved within a range of $1.3200 – 1.3600after opening the trade at $1.34.